<span item_type="fundamental" item_id="01807499138b276d3bb84047afe06d29" counter_id="ST/US/TDACU" env="prod"></span><span item_type="announcement" item_id="516479768921965697" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.07.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of March 31, 2025, since it is a blank check company focused on identifying a target for a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income</strong>: For the three months ended March 31, 2025, the company reported a net income of $1,483,074, primarily due to dividends earned on marketable securities held in the Trust Account amounting to $1,830,482, offset by general and administrative costs of $347,408.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li><li><strong>General and Administrative Costs</strong>: These costs were $347,408 for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: The net cash used in operating activities was - $231,574 for the three months ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Marketable Securities Held in Trust Account</strong>: As of March 31, 2025, the company held $176,180,828 in marketable securities in the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company intends to complete a business combination using the funds from its Initial Public Offering and Private Placement Warrants. It aims to use the proceeds from the Trust Account to finance the operations of the target business or businesses, make other acquisitions, and pursue growth strategies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has no current operations and is focused on identifying a target for a business combination. It has not engaged in any operations or generated any revenues to date.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1926599/000141057825001344/tdac-20250331x10q.htm"></span></li></ul>

Translational Development Acquisition - Unit | 10-Q: FY2025 Q1 EPS: USD 0.07